ICS 2024
Podium Short Oral Session 26 Female Pelvic Floor Dysfunction 273 Day to day challenges of living with obesity and incontnence: a qualitative exploration
Podium Short Oral Session 27 Biomechanics 289 Walking in Wet Pads: A clinical investigation of changes in gait associated with walking in soaked continence containment products in older women
Open Discussion Session 105 Open Discussion ePosters 645 A comparative study of the efficacy and comfort of the Purewick™ male external catheter in healthy volunteers
ICS 2023
Podium Session 32 Best Conservative Management 272 Are frailty, comorbidity and age related to overactive bladder? A cohort study
Podium Short Oral Session 35 Outcomes, Associations and Quality of Life 291 Management of Urinary Incontinence in Hospitalized Older Adults with Dementia – a Scoping Review
ICS 2020
Open Discussion Session 8 ePoster 2 126 A COMPARATIVE ASSESSMENT OF FRAILTY AND COMORBIDIITY IN OLDER PATIENTS WITH AND WITHOUT OVERACTIVE BLADDER
Open Discussion Session 12 ePoster 3 184 A PARALLEL ARM, CONTROLLED TRIAL OF THE EFFECTIVENESS OF A SMART SENSOR FOR CONTINENCE CARE (THE ARCTICC STUDY)
Podium Short Oral Session 27 Geriatrics and Special Population 418 EXPLORING OLDER ADULTS PRIORITIES OF URINARY INCONTINENCE; A COMMUNITY PARTICIPATORY BASED RESEARCH APPROACH
Open Discussion Session 32 ePoster 7 479 END USER VIEWS OF THE UTILITY AND IMPACT OF A SMART SENSOR FOR CONTINENCE CARE IN NURSING HOME RESIDENTS
ICS 2019
Podium Short Oral Session 8 Overactive Bladder 183 Response and cognitive safety of fesoterodine in patients >65y old with OAB. Is there a relationship between cognition and treatment response?
Podium Short Oral Session 20 Geriatrics 436 Maintaining urinary continence. A 12-month follow-up of elderly village women completing a six-month exercise intervention in Bangladesh
Podium Short Oral Session 20 Geriatrics 438 Effect of flexible dose fesoterodine on cognitive function in >65 year old patients with OAB: Data from two RCT
ICS 2018
Open Discussion Session 7 Open Discussion ePosters 151 Symptom relief from OAB: what an"average" patient might expect: data from a pooled analysis of Fesoterodine treated patients
Open Discussion Session 7 Open Discussion ePosters 152 How common are adverse events in patients with either a 50 or 100% resolution of OAB symptoms during treatment with fesoterodine?
Podium Short Oral Session 9 Products 204 Containment products and quality of life in men with light to moderate urinary incontinence: an exploratory analysis.
Podium Short Oral Session 15 Overactive Bladder 1 268 A Phase 4, double-blind, randomized, placebo-controlled, parallel group, multi-centre study to evaluate the efficacy, safety, and tolerability of mirabegron in older adult patients with overactive bladder syndrome (PILLAR)
Open Discussion Session 28 Open Discussion ePosters 583 Effect of pad use on quality of life in women with urinary incontinence: a mixed methods study
Open Discussion Session 28 Open Discussion ePosters 584 Containment products and quality of life in men with urinary incontinence: an exploratory, qualitative study
Podium Short Oral Session 30 Epidemiology and Prevention 621 The current state of continence in Canada: a population representative epidemiological survey.
Open Discussion Session 7 Open Discussion ePosters 96 With what degree of improvement in Patient Reported Outcome Measures is resolution of OAB symptoms associated? Data from a pooled analysis of OAB treatment with fesoterodine.
ICS 2017
Open Discussion Session 9 Open Discussion ePosters 1 205 Antimuscarinics and cognition – can we detect a “real-life” association?
Podium Short Oral Session 17 Health Services Research 299 What treatments for urinary incontinence and lower urinary tract symptoms are acceptable and what outcomes desirable to older people?
Podium Short Oral Session 3 Female Pelvic Floor Dysfunction 30 Is the belief that urinary incontinence is normal for aging related to older women’s experience of UI?
Podium Short Oral Session 8 Conservative Management Products 76 Time in soiled pads: What’s acceptable to older patients and what do direct caregivers think?
ICS 2016
Podium Short Oral Session 28 Pelvic Pain and Urinary Tract Infection 564 Economic and clinical impact of mirabegron compared with antimuscarinics for the treatment of overactive bladder in Canada
ICS 2015
Podium Short Oral Session 17 Treating the Frail Older Adult 240 Development and testing of a continence record for use with illiterate older women in rural Bangladesh
Podium Short Oral Session 17 Treating the Frail Older Adult 246 Development and testing of a community based exercise intervention for urinary incontinence in elderly village women in rural Bangladesh
ICS 2013
Podium Session 24 LUTS in Women 2 217 LOWER URINARY TRACT SYMPTOMS AND FALLS IN WOMEN: A CASE CONTROL STUDY
ICS 2011
Podium Session 13 Male Incontinence Assessment and Treatment 135 USE OF THE DRE IN MALE CONTINENCE/LUTS ASSESSMENT; A DYING ART? DATA FROM A NATIONAL AUDIT
Podium Poster Session 23 Continence Hotch Potch 234 Do older women with urinary incontinence receive evidence informed care?
Podium Poster Session 6 Male Lower Urinary Tract and Surgery 59 NICE compliant initial assessment of men with LUTS: How close is clinical practice to best practice? Data from a national audit in the UK.
ICS/IUGA 2010
Non Discussion Poster Session 31 395 PERSISTENCE PATTERNS WITH ORAL ANTIMUSCARINICS USED FOR THE TREATMENT OF OVERACTIVE BLADDER IN UK GENERAL PRACTICE: A RETROSPECTIVE ANALYSIS BY AGE
ICS 2009
Podium Session 12 Epidemiology 129 Does good organisational structure lead to quality care provision for older people with incontinence ?
Non Discussion Poster Session 32 334 Management of urinary incontinence in older people with a stroke: what’s the state of play?
Non Discussion Poster Session 32 387 A cross sectional study of ultrasound estimated bladder weight in men and women without lower urinary tract symptoms
Podium Poster Session 6 Quality of Life & Epidemiology 55 A qualitative study of the impact of caring for a person with urinary incontinence
ICS 2007
Non Discussion Poster Session 17 133 NATIONAL AUDIT OF CONTINENCE CARE FOR OLDER PEOPLE: MEASURING CHANGE IN ACUTE HOSPITALS: TOWARDS INTEGRATED CARE
Non Discussion Poster Session 17 154 Medication for urinary incontinence in older women: is use predicted by bother, severity or impact on quality of life?
Non Discussion Abstract Session 19 Read By Title 340 A description of the treatment of urinary incontinence in women over 65 years from a six month prospective observational study in the UK/RoI
Dr. Adrian Wagg MB BS FRCP FHEA qualified from the London Hospital Medical
College in 1988. He trained in General Internal and Geriatric medicine in and around London and was appointed as a Senior Lecturer and Consultant in General Internal and Geriatric Medicine to University College London Hospitals in 1997 and now holds the Chair of Healthy Ageing at the University of Alberta. He has developed and maintained an academic and clinical interest in urinary incontinence, and has published over 90 peer reviewed publications, chapters and reviews on the subject. He has spoken widely and is internationally recognised. His interests are in incontinence in the elderly, the effects of medication and co-morbidity on continence status and the epidemiology and aetiology of incontinence in the elderly. Until he l;eft the UK he led the continence in older people programme and a national audit of continence care. He chaired the 5th ICI committee on the Frail Elderly and has been involved in national and international guideline development
As a trustee of the ICS he has been instrumental in promoting the multiprofessional nature of the ICS and active in ensuring the Annual Scientific Meetings meet the needs of its members. He has pursued sound governance of ICS and has promoted ethical cost control associated with the Annual meeting social events. He is a firm believer in the ICS as a strong multiprofessional organisation built upon the excellence of its scientific and educational mission and will strive to promote ICS as the premier organisation in the field.
As member of the Education committee he led the reorganisation of the committee and introduced fair process for the selection of ICS speakers and educational activities outside the ASM and has recently taken a lead in promoting educational quality, producing with the subcommittee, vopcasts on powerpoint presentation and good chairmanship skills
Prof Adrian Stuart Wagg declared on the Tuesday 9th January 2024 that they had the following existing or known future financial relationships or affiliations:
Astellas Pharma
Pierre Fabre Medicaments
Becton-Dickinson
- Speaker Honorarium
- Trial participation
Urovant Sciences
- Speaker Honorarium
- Trial participation
International Consultation on Incontinence
Essity AB
- Consultant
- Research grant
Pfizer
- Other: spouse is an employee
UP TO DATE!